{'fraction_non_alphanumeric': 0.027777777777777776, 'fraction_numerical': 0.023148148148148147, 'mean_word_length': 5.791428571428572, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic Relationships between Veterans and Buprenorphine Providers and Effects on Treatment Retention.

OBJECTIVE
To examine the extent to which there was any therapeutic relationship between Veterans and their initial buprenorphine provider, and whether presence of this relationship influenced treatment retention.


DATA SOURCES
National, secondary administrative data used from the Veterans Health Administration (VHA), 2008-2017.


STUDY DESIGN
Retrospective cohort study. The primary exposure was a therapeutic relationship between the Veteran and buprenorphine provider, defined as the presence of previous visit or medication prescribed by the provider in the two years preceding buprenorphine treatment initiation. The primary outcome was treatment discontinuation, evaluated as 14 days of absence of medication from initiation through 1 year.


DATA COLLECTION/EXTRACTION METHODS
Adult Veterans (age ≥18 years) diagnosed with opioid use disorder and treated with buprenorphine or buprenorphine/ naloxone within the VHA system were included in this study. We excluded those receiving buprenorphine patches, those with a documentation of a metastatic tumor diagnosis within two years prior to buprenorphine initiation, and those without geographical information on rurality.


PRINCIPAL FINDINGS
A total of 28,791 Veterans were included in the study. Within the overall study sample, 56.3% (n=16,206) of Veterans previously had at least one outpatient encounter with their initial buprenorphine provider and 24.9% (n=7,174) of Veterans previously had at least one prescription from that provider in the two years preceding buprenorphine initiation. There was no significant or clinically meaningful association between therapeutic relationship history and treatment retention when defined as visit history (aHR: 0.99; 95%CI: 0.96-1.02) or medication history (aHR: 1.03; 95%CI: 1.00, 1.07).


CONCLUSIONS
Veterans initiating buprenorphine frequently did not have a therapeutic history with their initial buprenorphine provider, but this relationship was not associated with treatment retention. Future work should investigate how the quality of Veteran-provider therapeutic relationships influences OUD management, and whether eliminating training requirements for providers might affect access to buprenorphine, and subsequently treatment initiation and retention.